1
Immunization Recommendations for Human Papillomavirus and Hepatitis B
Chamberlain University
NR566: Advanced Pharmacology for Care of the Family
, 2
Immunization Recommendations for Human Papillomavirus and Hepatitis B
The purpose of this paper is to educate the community on two vaccinations that are
recommended for preventable illnesses in the United States. The two vaccines that will be
discussed are the human papillomavirus vaccine and the hepatitis B vaccine. These two vaccines
will be further broken down into trade names, classification of the vaccination, contraindications,
precautions, adverse drug reactions, routinely recommended schedules, and special situations.
Lastly, barriers and interventions will be discussed. This includes vaccine hesitancy, an
intervention to improve compliance, and healthcare providers’ responsibility in vaccine
reporting.
Human Papillomavirus Vaccine (HPV)
HPV’s trade name is Gardasil 9 (Centers for Disease Control and Prevention, 2020b).
HPV is considered a subunit, recombinant, polysaccharide, and conjugate vaccine (U.S.
Department of Health & Human Services, 2020). Contraindications for this vaccine are severe
allergic reactions, such as anaphylaxis, after a previous dose or to a vaccine component,
including yeast (Centers for Disease Control and Prevention, 2020b). Those with moderate or
severe acute illness with or without fever should be precautious when being administered this
vaccine (Centers for Disease Control and Prevention, 2020b). Adverse drug reactions to this
vaccine are syncope, soreness, redness, or swelling at the site of injection, fever, or headache
(Centers for Disease Control and Prevention, 2020a). The minimum age to receive the vaccine is
nine years old for the first dose and nine years plus five months for the second dose (Centers for
Disease Control and Prevention, 2020c). The Center for Disease Control and Prevention has
recommended a two-dose series for HPV. If the two-dose series is administered incorrectly, there
is an option for a three-dose series. The first injection (HPV-1) in the two-dose series is
Immunization Recommendations for Human Papillomavirus and Hepatitis B
Chamberlain University
NR566: Advanced Pharmacology for Care of the Family
, 2
Immunization Recommendations for Human Papillomavirus and Hepatitis B
The purpose of this paper is to educate the community on two vaccinations that are
recommended for preventable illnesses in the United States. The two vaccines that will be
discussed are the human papillomavirus vaccine and the hepatitis B vaccine. These two vaccines
will be further broken down into trade names, classification of the vaccination, contraindications,
precautions, adverse drug reactions, routinely recommended schedules, and special situations.
Lastly, barriers and interventions will be discussed. This includes vaccine hesitancy, an
intervention to improve compliance, and healthcare providers’ responsibility in vaccine
reporting.
Human Papillomavirus Vaccine (HPV)
HPV’s trade name is Gardasil 9 (Centers for Disease Control and Prevention, 2020b).
HPV is considered a subunit, recombinant, polysaccharide, and conjugate vaccine (U.S.
Department of Health & Human Services, 2020). Contraindications for this vaccine are severe
allergic reactions, such as anaphylaxis, after a previous dose or to a vaccine component,
including yeast (Centers for Disease Control and Prevention, 2020b). Those with moderate or
severe acute illness with or without fever should be precautious when being administered this
vaccine (Centers for Disease Control and Prevention, 2020b). Adverse drug reactions to this
vaccine are syncope, soreness, redness, or swelling at the site of injection, fever, or headache
(Centers for Disease Control and Prevention, 2020a). The minimum age to receive the vaccine is
nine years old for the first dose and nine years plus five months for the second dose (Centers for
Disease Control and Prevention, 2020c). The Center for Disease Control and Prevention has
recommended a two-dose series for HPV. If the two-dose series is administered incorrectly, there
is an option for a three-dose series. The first injection (HPV-1) in the two-dose series is
